Azora Therapeutics develops AD04, an investigational treatment for alcohol use disorder and other addiction and related disorders. It last closed at $3.76 on Nov 17, down 1.31% on the day.
Only 1 firm rated AZR in the past 90 days, not enough for a consensus
Average 12-month target
$14.00
▲ 272.3% upside
Based on 1 analyst who set a price target on AZR in the past 90 days. The average target is $14.00, with a high of $14.00 and a low of $14.00, compared with the last close of $3.76.
Low $14.00Avg $14.00High $14.00
Blue marker: last close $3.76
Highest target$14.00
Average target$14.00
Lowest target$14.00
Latest rating changes
Jones TradingInitiated
Nov 2Buy$14
Date
Firm
Action
Rating
Price target
Nov 2
Jones Trading
Initiated
Buy
$14
Loading…
Whale Options Flow
90D
No whale options trades in AZR in the last 90 days.
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AZR is in one of them and how their past AZR trades turned out.
Azora Therapeutics is a clinical stage biopharmaceutical company that develops treatments for addiction and related disorders. Its lead candidate, AD04, is being developed for alcohol use disorder in patients with certain genetic profiles, identified using a companion genetic test. The company's main focus is completing clinical development for AD04 to meet regulatory requirements in the United States and Europe. It has no products approved for sale yet and is based in Encino, California.